SG11202007865VA - Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer - Google Patents
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancerInfo
- Publication number
- SG11202007865VA SG11202007865VA SG11202007865VA SG11202007865VA SG11202007865VA SG 11202007865V A SG11202007865V A SG 11202007865VA SG 11202007865V A SG11202007865V A SG 11202007865VA SG 11202007865V A SG11202007865V A SG 11202007865VA SG 11202007865V A SG11202007865V A SG 11202007865VA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- tissue factor
- drug conjugates
- factor antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862639891P | 2018-03-07 | 2018-03-07 | |
US201862736343P | 2018-09-25 | 2018-09-25 | |
PCT/US2019/021024 WO2019173523A1 (en) | 2018-03-07 | 2019-03-06 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007865VA true SG11202007865VA (en) | 2020-09-29 |
Family
ID=67845742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007865VA SG11202007865VA (en) | 2018-03-07 | 2019-03-06 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210030888A1 (en) |
EP (1) | EP3762032A4 (en) |
JP (2) | JP7471227B2 (en) |
KR (1) | KR20200130356A (en) |
CN (1) | CN112105388A (en) |
AU (1) | AU2019231696A1 (en) |
BR (1) | BR112020018092A2 (en) |
CA (1) | CA3091217A1 (en) |
IL (1) | IL276768A (en) |
MX (1) | MX2020008613A (en) |
SG (1) | SG11202007865VA (en) |
WO (1) | WO2019173523A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023005930A (en) * | 2020-11-26 | 2023-05-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Combined pharmaceutical composition of anti-pd-l1 antibody and c-met kinase inhibitor for treating lung cancer. |
CN114569734B (en) * | 2022-01-17 | 2023-08-29 | 北京化工大学 | Preparation method of nanoparticle for delivering cationic platinum drug based on reduction-sensitive polymer |
WO2023213960A1 (en) * | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
WO2024067864A1 (en) * | 2022-09-30 | 2024-04-04 | Shanghai Junshi Biosciences Co., Ltd. | Anti-lair1 antibodies and their uses |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111012921A (en) * | 2010-06-15 | 2020-04-17 | 根马布股份公司 | Human antibody drug conjugates against tissue factor |
JP6978409B2 (en) | 2015-09-11 | 2021-12-08 | ゲンマブ エー/エス | Anti-TF antibody drug conjugate dosing regimen |
-
2019
- 2019-03-06 JP JP2020546443A patent/JP7471227B2/en active Active
- 2019-03-06 US US16/978,539 patent/US20210030888A1/en active Pending
- 2019-03-06 WO PCT/US2019/021024 patent/WO2019173523A1/en unknown
- 2019-03-06 KR KR1020207028401A patent/KR20200130356A/en unknown
- 2019-03-06 SG SG11202007865VA patent/SG11202007865VA/en unknown
- 2019-03-06 AU AU2019231696A patent/AU2019231696A1/en active Pending
- 2019-03-06 EP EP19764722.5A patent/EP3762032A4/en active Pending
- 2019-03-06 MX MX2020008613A patent/MX2020008613A/en unknown
- 2019-03-06 CN CN201980031334.6A patent/CN112105388A/en active Pending
- 2019-03-06 BR BR112020018092-0A patent/BR112020018092A2/en unknown
- 2019-03-06 CA CA3091217A patent/CA3091217A1/en active Pending
-
2020
- 2020-08-17 IL IL276768A patent/IL276768A/en unknown
-
2024
- 2024-01-12 JP JP2024002970A patent/JP2024045219A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2024045219A (en) | 2024-04-02 |
WO2019173523A1 (en) | 2019-09-12 |
KR20200130356A (en) | 2020-11-18 |
AU2019231696A1 (en) | 2020-09-03 |
BR112020018092A2 (en) | 2020-12-22 |
CA3091217A1 (en) | 2019-09-12 |
JP7471227B2 (en) | 2024-04-19 |
CN112105388A (en) | 2020-12-18 |
IL276768A (en) | 2020-10-29 |
EP3762032A1 (en) | 2021-01-13 |
MX2020008613A (en) | 2020-09-21 |
US20210030888A1 (en) | 2021-02-04 |
EP3762032A4 (en) | 2021-12-22 |
JP2021515017A (en) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL270814A (en) | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer | |
IL288485A (en) | Anti-trop2 antibody-drug conjugates for use in treating cancer | |
IL276768A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
IL277854A (en) | Antibody-drug conjugates and their uses for the treatment of cancer | |
ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
IL274122A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
IL266623A (en) | Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer | |
IL280867A (en) | Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof | |
ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
IL280510A (en) | Antibody-drug conjugates for use in the treatment of metastatic brain tumor | |
IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
IL278988A (en) | Anti-her2 antibody-drug conjugates for use in the treatment of her-2 mutated cancer | |
IL287391A (en) | Amatoxin antibody-drug conjugates and uses thereof | |
IL283787A (en) | Herboxidiene antibody-drug conjugates and methods of use | |
IL289138A (en) | Anti-tissue factor antibody-drug conjugates and related methods | |
EP3599249A4 (en) | Anti-5t4 antibody-drug conjugate and use thereof | |
EP3897725A4 (en) | Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer | |
IL280617A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
IL286334A (en) | Modified micrornas and their use in the treatment of cancer | |
IL291643A (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
GB201820659D0 (en) | Novel compostions and their use in therapy | |
IL291312A (en) | Anti-ptcra antibody-drug conjugates and uses thereof | |
IL277875A (en) | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy | |
IL277038A (en) | Bexarotene derivatives and their use in treating cancer | |
SG11202105276TA (en) | Oligo-benzamide analogs and their use in cancer treatment |